Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to 526.49%.

  • Ocular Therapeutix's EBIT Margin fell 2304100.0% to 526.49% in Q4 2025 from the same period last year, while for Dec 2025 it was 519.75%, marking a year-over-year decrease of 2501700.0%. This contributed to the annual value of 519.75% for FY2025, which is 2501800.0% down from last year.
  • Ocular Therapeutix's EBIT Margin amounted to 526.49% in Q4 2025, which was down 2304100.0% from 472.35% recorded in Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's EBIT Margin peaked at 127.41% during Q3 2023, and registered a low of 597.47% during Q1 2025.
  • In the last 5 years, Ocular Therapeutix's EBIT Margin had a median value of 176.35% in 2022 and averaged 255.5%.
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 9671900bps in 2021, then plummeted by -3834600bps in 2025.
  • Over the past 5 years, Ocular Therapeutix's EBIT Margin (Quarter) stood at 146.64% in 2021, then rose by 6bps to 137.56% in 2022, then rose by 2bps to 135.46% in 2023, then tumbled by -119bps to 296.08% in 2024, then plummeted by -78bps to 526.49% in 2025.
  • Its EBIT Margin stands at 526.49% for Q4 2025, versus 472.35% for Q3 2025 and 502.57% for Q2 2025.